# A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

> **NCT05345938** · PHASE1,PHASE2 · TERMINATED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome

## Key facts

- **NCT ID:** NCT05345938
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-14
- **Primary completion:** 2022-11-19
- **Final completion:** 2022-11-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Adjust the research strategy.
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05345938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05345938, "A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT05345938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*